The highly electrophilic, coordinatively unsaturated, 16-electron [Ru(P(OH)3)(dppe)2][OTf]2 (dppe = Ph2PCH2CH2PPh2) complex 1 activates the H-H, the Si-H, and the B-H bonds, in H2(g), EtMe2SiH and Et3SiH, and H3B.L (L = PMe3, PPh3), respectively, in a heterolytic fashion. The heterolysis of H2 involves an eta2-H2 complex (observable at low temperatures), whereas the computations indicate that those of the Si-H and the B-H bonds proceed through unobserved eta1-species. The common ruthenium-containing product in these reactions is trans-[Ru(H)(P(OH)3)(dppe)2][OTf], 2. The [Ru(P(OH)3)(dppe)2][OTf]2 complex is unique with regard to activating the H-H, the Si-H, and the B-H bonds in a heterolytic manner. These reactions and the heterolytic activation of the C-H bond in methane by the model complex [Ru(POH)3)(H2PCH2CH2PH2)2][Cl][OTf], 4, have been investigated using computational methods as well, at the B3LYP/LANL2DZ level. While the model complex activates the H-H, the Si-H, and the B-H bonds in H2, SiH4, and H3B.L (L = PMe3, PPh3), respectively, with a low barrier, activation of the C-H bond in CH4 involves a transition state of 57.5 kcal/mol high in energy. The inability of the ruthenium complex to activate CH4 is due to the undue stretching of the C-H bond needed at the transition state, in comparison to the other substrates.
No takes yet. Share an insight, caveat, or question.
Nagaraja et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: